Urologix Names Interim CEO

Minneapolis, Minn.-based Urologix Inc.’s CEO Stryker Warren resigned at the end of November. Replacing him as interim CEO is Gregory Fluet, who has served as the company’s chief operating officer and executive vice president since 2008.

“Stryker has provided the right leadership at a critical time in Urologix’s history,” said Urologix’s Chairman Mitchell Dann. “His urology relationships and commitments to patients and employees helped transform the company.”

Warren will remain on the company books until March 2013, and will thereafter serve as a consultant. According to a securities exchange commission filing announcing the staff change, Warren will be on the payroll for $1,000 for every eight hours worked. According to company officials, during his four year tenure as CEO, Warren revitalized Urologix’s relationships with the urologic community, organized the original patient education initiatives that have become the principal driver of the company’s growth strategy, built a strong leadership team to include the recruitment of Fluet and steered the company through a difficult decline in the in-office benign prostatic hyperplasia (BPH) therapy market.

Fluet is a 1991 graduate of Stanford University, where he studied mechanical engineering. He has been a board observer of Hansen Medical, a robotics company, and a project manager at Freeman, Sullivan & Co., an energy consulting firm. He has experience assisting portfolio companies with intellectual property, financial analysis, market research, and clinical research. Fluet joined Sapient Capital Management in the spring of 2002 and worked as an analyst and an associate until 2008, when he joined Urologix. He is also currently a consultant at Sapient Capital Management LLC.

“Greg has been a key member of the executive team during Stryker’s tenure and the board is confident he can lead the company during this transition period,” added Dann. “The board has begun the process of looking for a permanent CEO.”

Urologix develops minimally invasive medical products for the treatment of obstruction and symptoms due to BPH.